CD30 expression by IHC
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD30-IHC |
|---|---|
| Type | Biomarker |
| Aliases | CD30 expressionЕкспресія CD30 (імуногістохімія) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy Unitscategorical (positive ≥10% | negative) |
| Related biomarkers | None declared |
Notes
Universal CD30+ in systemic ALCL. ~40-60% PTCL NOS / AITL. Required for brentuximab vedotin-based regimens (CHP-Bv, A+AVD).
Used By
Actionability
BMA-CD30-ALCL- CD30 expression is a defining feature of anaplastic large-cell lymphoma (sALCL); brentuxi...BMA-CD30-CHL- CD30 is universally expressed on Reed-Sternberg cells in classical Hodgkin lymphoma and i...
Biomarker
BIO-MUM1-IHC- MUM1/IRF4 IHC (Multiple Myeloma oncogene 1)
Indications
IND-AITL-1L-CHP-BV- IND-AITL-1L-CHP-BVIND-ALCL-2L-BRENTUXIMAB-MONO- IND-ALCL-2L-BRENTUXIMAB-MONOIND-ALCL-MAINTENANCE-BV-POST-ASCT- IND-ALCL-MAINTENANCE-BV-POST-ASCTIND-MF-ADVANCED-1L-BV- IND-MF-ADVANCED-1L-BVIND-TCELL-1L-CHP-BV- IND-TCELL-1L-CHP-BV
Questionnaires
QUEST-AITL-1L-STUB- Angioimmunoblastic T-Cell Lymphoma — first lineQUEST-ALCL-1L-STUB- Anaplastic Large Cell Lymphoma, Systemic — first lineQUEST-MF-SEZARY-1L-STUB- Mycosis Fungoides / Sézary Syndrome — first line
Red flag
RF-TCELL-CD30-POSITIVE- T-cell lymphoma with CD30 expression ≥10% by IHC — qualifies for brentuximab vedotin-base...